Evidence map›Paper›PMID 27825119›Full record

ArticleOncotarget2016

Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro.

Soochi Kim, HyeRan Gwak, Hee Seung Kim, Boyun Kim, Danny N Dhanasekaran, Yong Sang Song

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Processing and Analysis of Ascites.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Ovarian cancer stem cells: ready for prime time?Archives of gynecology and obstetrics · 2020
    Review
  20. Prognostic and Clinical Value of Interleukin 6 and CD45Journal of immunology research · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Soochi KimInterdisciplinary Program in Cancer Biology, College of Medicine, Seoul National University, Seoul, Republic of Korea.
HyeRan GwakCancer Research Institute, Seoul National University, Seoul, Republic of Korea.
Hee Seung KimCancer Research Institute, Seoul National University, Seoul, Republic of Korea.
Boyun KimCancer Research Institute, Seoul National University, Seoul, Republic of Korea.
Danny N DhanasekaranStephenson Cancer Center, University of Oklahoma Health Sciences Center, USA.
Yong Sang SongInterdisciplinary Program in Cancer Biology, College of Medicine, Seoul National University, Seoul, Republic of Korea.
Seoul National University · KRUniversity of Oklahoma Health Sciences Center · US

Funding

G Proteins and Their Receptors in Tumor Cell MetastasisR01CA116984 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI DHANASEKARAN, DANNY N. · 2007 to 2011
$1.5M
NCI NIH HHS R01 CA116984
6 · The paper itself

Abstract

Transcoelomic route is the most common and the earliest route of metastasis, causing the ascites formation in advanced epithelial ovarian cancer (EOC). We demonstrated that interleukin 6 (IL-6) is enriched in the malignant ascites from patients with ovarian cancer, which enhanced invasive properties of EOC cells. Interestingly, the expression of IL-6R on cell membrane of EOC cells correlated with ascites-induced invasion. Selective knockdown of IL-6R or inhibition with IL-6 neutralizing antibody, suppressed the stimulatory effects of ascites on EOC invasion. Moreover, the ascites treatment induced the phosphorylation of JAK2-STAT3 and use of selective inhibitors of JAK2 and STAT3, blocked the expression of epithelial-mesenchymal transition related proteins in parallel with the suppression of EOC invasion. Thus, IL-6/IL-6R mediated JAK2-STAT3 signaling pathway could be a promising therapeutic target for anticancer therapy in ovarian cancer patients with ascites.

Indexed as

AscitesCell MovementAgedAntibodies, NeutralizingAntineoplastic AgentsAscitic FluidCarcinoma, Ovarian EpithelialCell Line, TumorCell MembraneEpithelial-Mesenchymal TransitionFemaleHumansInterleukin-6Janus Kinase 2Middle AgedNeoplasm InvasivenessAntibodies, NeutralizingAntineoplastic AgentsIL6 protein, humanIL6R protein, humanInterleukin-6JAK2 protein, humanJanus Kinase 2Protein Kinase InhibitorsReceptors, Interleukin-6STAT3 protein, humanSTAT3 Transcription FactorascitesIL-6Rinvasionmigrationovarian cancer

Identifiers

PMID27825119
PMCPMC5347759
OpenAlexW2548838471

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.